Congress Materials – American Association of Psychiatric Pharmacists (AAPP 2026)
2026 American Association of Psychiatric Pharmacists | Apr 19-22 | Seattle, WA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Adjunctive Lumateperone in Patients With Major Depressive Disorder and Anxious Distress
Suresh Durgam, MD; Willie R. Earley, MD; Susan G. Kozauer, MD; Myaa Lightfoot, PharmD; Yifan Mo, PhD; Rakesh Jain, MD, MPH
Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder
Anita H. Clayton, MD; Willie R. Earley, MD; Susan G. Kozauer, MD; Yifan Mo, PhD; Betsy Yuan, PharmD, BCPP; John B. Edwards, MD; Suresh Durgam, MD
Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials
Zubin Bhagwagar, MD, DPhil; Suresh Durgam, MD; Willie R. Earley, MD; Changzheng Chen, PhD; Mitchell Crouch, PharmD; Michael E. Thase, MD
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.